GenVec Inc (fka GNVC)

[Camaro1093]

Encouraging Data From Malaria Study Presented

GAITHERSBURG, Md., April 12, 2010 /PRNewswire via COMTEX/ -- GenVec, Inc. (GNVC)
announced that encouraging clinical and preclinical malaria vaccine data were
presented at the Keystone Symposium -- Malaria: New Approaches to Understanding
Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain,
Colorado.

Safety, tolerability, immunogenicity, and efficacy data from the Phase 1/2a
malaria trial using GenVec technology were presented. Data indicate malaria
vaccines given to malaria-naive adults were found to be safe and well-tolerated
with minimal local or systemic reactions and no serious vaccine-related adverse
reactions. Sterile protection, a complete absence of parasites in the blood, was
seen in 4 out of 15 volunteers that had been inoculated with the vaccine and
subsequently challenged with the malaria parasite.

This clinical trial is being conducted under sponsorship from the United States
Army Medical Materiel Development Activity (USAMMDA) and with financial support
from the U.S. Agency for International Development, the Congressionally Directed
Peer Review Medical Program, and the Military Infectious Diseases Research
Program.

"The results of this study are encouraging and we are looking forward to gaining
more insight regarding the potential for this vaccine," stated Dr. Douglas
Brough, GenVec's Vice President of Research.

About Malaria

Malaria is one of the world's leading lethal infectious diseases. Malaria is a
life-threatening disease transmitted to humans through the bite of an infected
mosquito. Malaria parasites initially invade liver cells and, after multiplying,
release tens of thousands of new parasites, which invade red blood cells,
multiply again, and then destroy these cells. High fever, headache, and vomiting
appear approximately nine to fourteen days after the infectious bite. If
untreated, the infection can progress rapidly and become life threatening --
destroying red blood cells, causing severe anemia, and blocking capillaries that
carry blood to the brain, resulting in coma and/or death. Malaria causes
approximately 243 million acute illnesses and 863,000 deaths annually, mostly
among children under the age of five. Malaria is a major health risk for
travelers and the military.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs
and vaccines. GenVec uses its proprietary adenovector technology to develop
TNFerade for the treatment of certain cancers and vaccines for infectious
diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory
syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel
treatments for hearing loss and balance disorders through a worldwide
collaboration with Novartis. Additional information about GenVec is available at
http://www.genvec.com and in the Company's various filings with the Securities
and Exchange Commission.

Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters, including
expectations regarding future revenues and operating expenses, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act. GenVec cautions that these forward-looking statements are
subject to numerous assumptions, risks and uncertainties, which change over time.
Factors that may cause actual results to differ materially from the results
discussed in the forward-looking statements or historical experience include
risks and uncertainties, including the failure by GenVec to secure and maintain
relationships with collaborators; risks relating to the early stage of GenVec's
product candidates under development; uncertainties relating to clinical trials;
risks relating to the commercialization, if any, of GenVec's proposed product
candidates; dependence on the efforts of third parties; dependence on
intellectual property; and risks that we may lack the financial resources and
access to capital to fund our operations. Further information on the factors and
risks that could affect GenVec's business, financial conditions and results of
operations, are contained in GenVec's filings with the U.S. Securities and
Exchange Commission (SEC), which are available at http://www.sec.gov. These
forward-looking statements speak only as of the date of this press release, and
GenVec assumes no duty to update forward-looking statements.



Investor Contact:Media Contact:
Tiberend Strategic Advisors,
GenVec, Inc.Inc.
Danielle M.
DiPirroAndrew Mielach
[phone](212) 827-0020
[e-mail]@tiberendstrategicadvisors.com





SOURCE GenVec, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved